The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer.
Panagiotis Konstantinopoulos
No relevant relationships to disclose
Vicky Makker
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Joyce Liu
No relevant relationships to disclose
Neil S. Horowitz
No relevant relationships to disclose
Michael J. Birrer
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
Suzanne T. Berlin
No relevant relationships to disclose
Christin Whalen
No relevant relationships to disclose
Paul Van Hummelen
No relevant relationships to disclose
Robert L. Coleman
Consultant or Advisory Role - Merck (U)
Research Funding - Merck
Carol Aghajanian
No relevant relationships to disclose
Gordon B. Mills
Consultant or Advisory Role - AstraZeneca (U)
Research Funding - AstraZeneca; GlaxoSmithKline
Ursula Matulonis
No relevant relationships to disclose
Shannon Neville Westin
Research Funding - AstraZeneca
Andrea P. Myers
Employment or Leadership Position - Novartis
Consultant or Advisory Role - Sanofi
Stock Ownership - Novartis